Advertisement
Screener

Krystal Biotech, Inc. (KRYS) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Krystal Biotech, Inc. Stock-Based Compensation

Krystal Biotech, Inc. (KRYS) reported Stock-Based Compensation of $27.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-03

  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $14.16M, a 0.26% increase year-over-year.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.61M, a 0.97% increase year-over-year.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $13.76M, a 3.05% increase year-over-year.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $13.15M, a 1.22% decline year-over-year.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $54.51M, a 10.97% increase from fiscal 2024.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $49.13M, a 23.02% increase from fiscal 2023.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $39.93M, a 20.17% increase from fiscal 2022.
  • Krystal Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $33.23M, a 116.92% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$14.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
$27.77M
10-Q · filed 2026-08-03
$41.53M
derived: sum of 3 quarters · filed 2026-08-03
$54.68M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31$13.61M
10-Q · filed 2026-05-04
$27.37M
derived: sum of 2 quarters · filed 2026-05-04
$40.53M
derived: sum of 3 quarters · filed 2026-05-04
$54.65M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31$13.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$26.92M
derived: sum of 2 quarters · filed 2026-02-17
$41.04M
derived: sum of 3 quarters · filed 2026-08-03
$54.51M
10-K · filed 2026-02-17
2025-09-30$13.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$27.27M
derived: sum of 2 quarters · filed 2026-08-03
$40.75M
10-Q · filed 2025-11-03
$54.11M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$14.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
$27.60M
10-Q · filed 2026-08-03
$40.95M
derived: sum of 3 quarters · filed 2026-08-03
$54.27M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31$13.48M
10-Q · filed 2026-05-04
$26.83M
derived: sum of 2 quarters · filed 2026-05-04
$40.15M
derived: sum of 3 quarters · filed 2026-05-04
$53.31M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31$13.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$26.67M
derived: sum of 2 quarters · filed 2026-02-17
$39.83M
derived: sum of 3 quarters · filed 2026-02-17
$49.13M
10-K · filed 2026-02-17
2024-09-30$13.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$26.47M
derived: sum of 2 quarters · filed 2025-11-03
$35.77M
10-Q · filed 2025-11-03
$45.62M
derived: sum of 4 quarters · filed 2026-02-17
2024-06-30$13.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04
$22.45M
10-Q · filed 2025-08-04
$32.31M
derived: sum of 3 quarters · filed 2026-02-17
$40.62M
derived: sum of 4 quarters · filed 2026-02-17
2024-03-31$9.30M
10-Q · filed 2025-05-06
$19.15M
derived: sum of 2 quarters · filed 2026-02-17
$27.46M
derived: sum of 3 quarters · filed 2026-02-17
$38.80M
derived: sum of 4 quarters · filed 2026-02-17
2023-12-31$9.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$18.16M
derived: sum of 2 quarters · filed 2026-02-17
$29.50M
derived: sum of 3 quarters · filed 2026-02-17
$39.93M
10-K · filed 2026-02-17
2023-09-30$8.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04
$19.64M
derived: sum of 2 quarters · filed 2024-11-04
$30.08M
10-Q · filed 2024-11-04
$39.63M
derived: sum of 4 quarters · filed 2025-02-19
2023-06-30$11.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
$21.77M
10-Q · filed 2024-08-05
$31.32M
derived: sum of 3 quarters · filed 2025-02-19
$40.38M
derived: sum of 4 quarters · filed 2025-02-19
2023-03-31$10.44M
10-Q · filed 2024-05-06
$19.99M
derived: sum of 2 quarters · filed 2025-02-19
$29.05M
derived: sum of 3 quarters · filed 2025-02-19
$37.24M
derived: sum of 4 quarters · filed 2025-02-19
2022-12-31$9.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19
$18.61M
derived: sum of 2 quarters · filed 2025-02-19
$26.80M
derived: sum of 3 quarters · filed 2025-02-19
$33.23M
10-K · filed 2025-02-19
2022-09-30$9.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$17.25M
derived: sum of 2 quarters · filed 2023-11-06
$23.68M
10-Q · filed 2023-11-06
$28.82M
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$8.19M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$14.62M
10-Q · filed 2023-08-07
$19.76M
derived: sum of 3 quarters · filed 2024-02-26
$23.43M
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$6.43M
10-Q · filed 2023-05-08
$11.57M
derived: sum of 2 quarters · filed 2024-02-26
$15.24M
derived: sum of 3 quarters · filed 2024-02-26
$19.44M
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31$5.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$8.81M
derived: sum of 2 quarters · filed 2024-02-26
$13.01M
derived: sum of 3 quarters · filed 2024-02-26
$15.32M
10-K · filed 2024-02-26
2021-09-30$3.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$7.86M
derived: sum of 2 quarters · filed 2022-11-07
$10.17M
10-Q · filed 2022-11-07
$10.74M
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30$4.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$6.51M
10-Q · filed 2022-08-08
$7.08M
derived: sum of 3 quarters · filed 2023-02-27
$8.43M
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$2.31M
10-Q · filed 2022-05-09
$2.88M
derived: sum of 2 quarters · filed 2023-02-27
$4.24M
derived: sum of 3 quarters · filed 2023-02-27
$5.05M
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31$570.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$1.93M
derived: sum of 2 quarters · filed 2023-02-27
$2.73M
derived: sum of 3 quarters · filed 2023-02-27
$3.27M
10-K · filed 2023-02-27
2020-09-30$1.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$2.16M
derived: sum of 2 quarters · filed 2021-11-08
$2.70M
10-Q · filed 2021-11-08
$3.02M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$807.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$1.35M
10-Q · filed 2021-08-09
$1.67M
derived: sum of 3 quarters · filed 2021-08-09
$1.95M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$539.00K
10-Q · filed 2021-05-10
$862.00K
derived: sum of 2 quarters · filed 2021-05-10
$1.14M
derived: sum of 3 quarters · filed 2021-05-10
$1.47M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$323.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$601.00K
derived: sum of 2 quarters · filed 2021-03-01
$926.00K
derived: sum of 3 quarters · filed 2021-03-01
$1.24M
10-K · filed 2021-03-01
2019-09-30$278.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$603.00K
derived: sum of 2 quarters · filed 2020-11-09
$916.00K
10-Q · filed 2020-11-09
$1.22M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$325.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$638.00K
10-Q · filed 2020-08-07
$940.00K
derived: sum of 3 quarters · filed 2020-08-07
$1.22M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$313.00K
10-Q · filed 2020-05-04
$615.00K
derived: sum of 2 quarters · filed 2020-05-04
$893.00K
derived: sum of 3 quarters · filed 2020-05-04
$1.04M
derived: sum of 4 quarters · filed 2020-05-04
2018-12-31$302.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10
$580.00K
derived: sum of 2 quarters · filed 2020-03-10
$727.00K
derived: sum of 3 quarters · filed 2020-03-10
$792.00K
10-K · filed 2020-03-10
2018-09-30$278.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04
$425.00K
derived: sum of 2 quarters · filed 2019-11-04
$490.00K
10-Q · filed 2019-11-04
$548.00K
derived: sum of 4 quarters · filed 2019-11-04
2018-06-30$147.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05
$212.00K
10-Q · filed 2019-08-05
$270.00K
derived: sum of 3 quarters · filed 2019-08-05
$323.00K
derived: sum of 4 quarters · filed 2019-08-05
2018-03-31$65.00K
10-Q · filed 2019-05-07
$123.00K
derived: sum of 2 quarters · filed 2019-05-07
$176.00K
derived: sum of 3 quarters · filed 2019-05-07
$220.00K
derived: sum of 4 quarters · filed 2019-05-07
2017-12-31$58.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$111.00K
derived: sum of 2 quarters · filed 2018-11-05
$155.00K
derived: sum of 3 quarters · filed 2018-11-05
$246.00K
10-K · filed 2018-03-12
2017-09-30$53.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05
$97.00K
derived: sum of 2 quarters · filed 2018-11-05
$188.00K
10-Q · filed 2018-11-05
$214.00K
derived: sum of 4 quarters · filed 2018-11-05
2017-06-30$44.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
$135.00K
10-Q · filed 2018-08-06
$161.00K
derived: sum of 3 quarters · filed 2018-08-06
2017-03-31$91.00K
10-Q · filed 2018-05-07
$117.00K
derived: sum of 2 quarters · filed 2018-05-07
2016-12-31$26.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$33.00K
10-K · filed 2018-03-12
2016-09-30$7.00K
10-Q · filed 2017-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
REPLIGEN CORP (RGEN)United States$10.755B185.31
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Immunovant, Inc. (IMVT)United States$7.028B-14.78
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
CG Oncology, Inc. (CGON)United States$6.095B-27.95